Detection and Quantitation of Residual Host Cell DNA

All biological drug products are required to be characterised for safety, quality and efficacy. ICH Q6B gives clear guidance on the requirements for product characterisation including the detection of product and process related impurities. This white paper discusses an approach to monitoring the levels of residual DNA derived from the production host for the drug including consideration of practical control of contamination as well as the MHRA’s guidance on performing PCR analysis.

Interested in this service?

News & Events

Make an Enquiry